Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities

Leukemia

Volumn 26, Issue 3, 2012, Pages 550-554

  Vicente, C ^a,b   Vazquez, I ^a   Conchillo, A ^a   Garcia Sanchez M A ^a   Marcotegui, N ^a   Fuster, O ^c   Gonzalez M ^d   Calasanz, M J ^b   Lahortiga, I ^e   Odero, M D ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^e DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; CANCER SURVIVAL; FEMALE; GATA 2 GENE; GENE; GENE OVEREXPRESSION; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; FEMALE; GATA2 TRANSCRIPTION FACTOR; GENE EXPRESSION; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84857997066     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.235     Document Type: Letter

References (11)

1. Tsai FY, Keller G, Kuo FC, Weiss M, Chen J, Rosenblatt M et al. An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature 1994; 371: 221-226. (Pubitemid 24293019)
2. Huang Z, Dore LC, Li Z, Orkin SH, Feng G, Lin S et al. GATA-2 reinforces megakaryocyte development in the absence of GATA-1. Mol Cell Biol 2009; 29: 5168-5180.
3. Fadilah SA, Cheong SK, Roslan H, Rozie-Hanisa M, Yen GK. GATA-1 and GATA-2 gene expression is related to the severity of dysplasia in myelodysplastic syndrome. Leukemia 2002; 16: 1563-1565.
4. Shimamoto T, Ohyashiki K, Ohyashiki JH, Kawakubo K, Fujimura T, Iwama H et al. The expression pattern of erythrocyte/ megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia gene correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia. Blood 1995; 86: 3173-3180.
5. Ayala RM, Martinez-Lopez J, Albizua E, Diez A, Gilsanz F. Clinical significance of Gata-1, Gata-2, EKLF, and c-MPL expression in acute myeloid leukemia. Am J Hematol 2009; 84: 79-86.
6. Furuhata A, Murakami M, Ito H, Gao S, Yoshida K, Sobue S et al. GATA-1 and GATA-2 binding to 3′ enhancer of WT1 gene is essential for its transcription in acute leukemia and solid tumor cell lines. Leukemia 2009; 23: 1270-1277.
7. Yuasa H, Oike Y, Iwama A, Nishikata I, Sugiyama D, Perkins A et al. Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J 2005; 24: 1976-1987. (Pubitemid 40896169)
8. Lahortiga I, Vazquez I, Agirre X, Larrayoz MJ, Vizmanos JL, Gozzetti A et al. Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements. Genes Chromosomes Cancer 2004; 40: 179-189. (Pubitemid 38714029)
9. Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol 2010; 28: 2739-2747.
10. Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009; 27: 5195-5201.
11. Bullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, Tibshirani R et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004; 350: 1605-1616. (Pubitemid 38501163)